Glibenclamide And Metformin Oral Tablets (Immediate-Release) Suppliers & Bulk Manufacturers
Available Forms: Tablets IR
Available Strengths: Glibenclamide 2.5 mg + Metformin 500 mg; Glibenclamide 5 mg + Metformin 500 mg
Reference Brands: Glucovance®,®, Euglucon-M®, Glyburid-M®(EU & US)
Category:
Diabetes
This dual formulation combines Glibenclamide, a sulfonylurea that stimulates insulin secretion, and Metformin, which reduces hepatic glucose production and improves insulin sensitivity. The synergistic effect offers better glycemic control in type 2 diabetes, reducing fasting and postprandial glucose levels. It lowers HbA1c effectively and is suitable when monotherapy fails.
Glibenclamide and Metformin Oral Tablets (Immediate-Release) is available in Tablets IR
and strengths such as Glibenclamide 2.5 mg + Metformin 500 mg; Glibenclamide 5 mg + Metformin 500 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Glibenclamide and Metformin Oral Tablets (Immediate-Release) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Glibenclamide and Metformin Oral Tablets (Immediate-Release) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Glibenclamide (Glyburide) + Metformin tablets are approved in several EU countries under fixed-dose combinations and were previously marketed in the USA as Glucovance®. However, due to evolving safety guidelines—especially related to hypoglycemia risk—its availability may vary. In the EU, these combinations are still prescribed under close monitoring for type 2 diabetes management. The European Medicines Agency (EMA) requires risk-benefit evaluation and labeling for renal monitoring. The U.S. FDA formerly approved Glucovance® under NDA 021178. Healthcare buyers and distributors can find these formulations via Pharmatradz.com for compliant global sourcing.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing